tiprankstipranks

Royalty Pharma resumed with an Overweight at Morgan Stanley

Morgan Stanley resumed coverage of Royalty Pharma (RPRX) with an Overweight rating and $51 price target The firm cites se the company’s diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1